### Edgar Filing: PUMA BIOTECHNOLOGY, INC. - Form 4

	Lugai	i iiiig. i Oivi			LUU	1, 110	1 0111 4			
PUMA BIOT Form 4 May 21, 2015	ECHNOLOGY, INC.									
FORM A							OMB APPROVAL			
	UNITED STAT		SECURITIES AND EXCHANGE CO Washington, D.C. 20549					OMB Number:	3235-0287	
Check this if no longe subject to Section 16 Form 4 or Form 5 obligations may contir <i>See</i> Instruct 1(b).	r STATEMENT Filed pursuant t Section 17(a) of the	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							January 31, 2005 average rs per 0.5	
(Print or Type Responses)										
1. Name and Ad BRYCE RIC	Name <b>and</b> Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Month/Day/Year)							below)	ive title 10% Owner Other (specify below) IICAL RESEARCH & DEV		
LOS ANGEL	(Street) JES, CA 90024	Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State) (Zip)	Tabla	I Non Do	mizrativa S	aannit		ired, Disposed of,	or Ponoficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. (Month/Day/Year) Exe any	Transaction Date 2A. Deemed Ionth/Day/Year) Execution Date, if			ties A	cquired d of (D)	5. Amount of		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
COMMON STOCK	04/09/2014		Code V P	Amount 2	(D) A	Price \$ 87.35	2	D		
COMMON STOCK	04/11/2014		Р	28	A	\$ 82.49	30	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: PUMA BIOTECHNOLOGY, INC. - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Tran (Inst
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Relationships **Reporting Owner Name / Address** Officer Director 10% Owner **BRYCE RICHARD PAUL** C/O PUMA BIOTECHNOLOGY, INC. SR VP, CLINICAL RESEARCH & DEV 10880 WILSHIRE BLVD., SUITE 2150 LOS ANGELES, CA 90024 Signatures /s/ Richard Paul 05/21/2015 Bryce Date \*\*Signature of

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Person

### 2

Other